1. Home
  2. CGEN vs BGX Comparison

CGEN vs BGX Comparison

Compare CGEN & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.53

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$11.73

Market Cap

151.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEN
BGX
Founded
1993
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
143.1M
151.0M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
CGEN
BGX
Price
$1.53
$11.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
393.8K
67.9K
Earning Date
11-10-2025
01-01-0001
Dividend Yield
N/A
10.34%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,903,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$231.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.13
$10.69
52 Week High
$2.66
$12.44

Technical Indicators

Market Signals
Indicator
CGEN
BGX
Relative Strength Index (RSI) 44.41 41.42
Support Level $1.47 $11.06
Resistance Level $1.67 $11.90
Average True Range (ATR) 0.10 0.16
MACD -0.00 -0.01
Stochastic Oscillator 22.01 75.42

Price Performance

Historical Comparison
CGEN
BGX

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

Share on Social Networks: